R
Razelle Kurzrock
Researcher at University of California, San Diego
Publications - 1225
Citations - 66956
Razelle Kurzrock is an academic researcher from University of California, San Diego. The author has contributed to research in topics: Cancer & Medicine. The author has an hindex of 118, co-authored 1121 publications receiving 56594 citations. Previous affiliations of Razelle Kurzrock include Repligen Corporation & Washington University in St. Louis.
Papers
More filters
Journal ArticleDOI
PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy
TL;DR: Improved understanding of the host immune system and tumor microenvironment will better elucidate which patients derive benefit from these promising agents, and the issue of PD-L1 as an exclusionary predictive biomarker is clarified.
Journal ArticleDOI
Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers.
Aaron M. Goodman,Shumei Kato,Lyudmila Bazhenova,Sandip Pravin Patel,Garrett M. Frampton,Vincent A. Miller,Philip J. Stephens,Gregory A. Daniels,Razelle Kurzrock +8 more
TL;DR: Higher TMB predicts favorable outcome to PD-1/PD-L1 blockade across diverse cancers treated with various immunotherapies, and Benefit from dual checkpoint blockade did not show a similarly strong dependence on TMB.
Journal ArticleDOI
The biology of chronic myeloid leukemia
TL;DR: Although heterogeneous, CML is the best-characterized leukemia at a molecular level, and studies in recent years have helped to define further.
Journal ArticleDOI
Phase II Trial of Curcumin in Patients with Advanced Pancreatic Cancer
Navneet Dhillon,Bharat B. Aggarwal,Robert A. Newman,Robert A. Wolff,Ajaikumar B. Kunnumakkara,James L. Abbruzzese,Chaan S. Ng,Vladimir Badmaev,Razelle Kurzrock +8 more
TL;DR: Oral curcumin is well tolerated and, despite its limited absorption, has biological activity in some patients with pancreatic cancer.
Journal ArticleDOI
Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.
Gerald S. Falchook,Georgina V. Long,Georgina V. Long,Razelle Kurzrock,Kevin B. Kim,Tobias Arkenau,Michael P. Brown,Omid Hamid,Jeffrey R. Infante,Michael Millward,Michael Millward,Anna C. Pavlick,Steven J. O'Day,Samuel C. Blackman,C. Martin Curtis,Peter F. Lebowitz,Bo Ma,Daniele Ouellet,Richard F. Kefford,Richard F. Kefford +19 more
TL;DR: Efficacy at the recommended phase 2 dose was studied in patients with BRAF-mutant tumours, including those with non-Val600Glu mutations, in three cohorts: metastatic melanoma, melanoma with untreated brain metastases, and non-melanoma solid tumours.